Literature DB >> 17488193

Toll-like receptor 9 ligand blocks osteoclast differentiation through induction of phosphatase.

Alla Amcheslavsky1, Zvi Bar-Shavit.   

Abstract

UNLABELLED: CpG-ODN, in addition to stimulation of osteoclastogenic signals in early osteoclast precursors, also induces phosphatase, shifting the pattern of ERK phosphorylation from sustained to transient. This shift results in the degradation of c-fos, an essential molecule for osteoclast differentiation. Therefore, CpG-ODN blocks osteoclast differentiation.
INTRODUCTION: Activation of either Toll-like receptor 9 (TLR9) or RANK induces similar responses in osteoclast precursors. Paradoxically, activation of TLR9 results in inhibition of RANKL-induced osteoclastogenesis.
MATERIALS AND METHODS: We used bone marrow-derived osteoclast precursors. Analyses of signaling molecules phosphorylation were performed using Western blotting. Different levels of gene expression analyses were performed using RT-PCR, Northern, and run-on analyses (for RNA), and EMSA, Western, and pulse-chase experiments (for protein). Phosphatase activity was measured spectrophotometrically.
RESULTS: We found that RANKL and TLR9 ligand, oligodeoxynucleotides containing unmethylated CpG dinucleotides (CpG-ODN), induce sustained and transient extracellular signal-regulated kinase (ERK) phosphorylation, respectively. Furthermore, together they induce a transient phosphorylation of ERK. The duration of ERK phosphorylation is a key factor in determining induction of c-fos, a protein critical for osteoclastogenesis. Indeed, we found that CpG-ODN does not induce c-fos and inhibits its induction by RANKL by enhancing c-fos mRNA and protein degradation. Our observation that CpG-ODN, but not RANKL, induces the expression of the phosphatase PP2A suggests that CpG-ODN exerts its inhibitory activity by induction of ERK dephosphorylation. Moreover, together with the phosphatase inhibitor okadaic acid, CpG-ODN induces sustained ERK phosphorylation and c-fos expression.
CONCLUSIONS: Our findings suggest that the increased rate of c-fos degradation by the TLR9 ligand mediates the inhibition of RANKL-induced osteoclast differentiation. The TLR9 ligand, through induction of dephosphorylation, prevents the sustained ERK phosphorylation needed for maintaining high c-fos levels that are essential for osteoclast differentiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488193     DOI: 10.1359/jbmr.070501

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  10 in total

1.  IL-1R/TLR2 through MyD88 Divergently Modulates Osteoclastogenesis through Regulation of Nuclear Factor of Activated T Cells c1 (NFATc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1).

Authors:  Zhihong Chen; Lingkai Su; Qingan Xu; Jenny Katz; Suzanne M Michalek; Mingwen Fan; Xu Feng; Ping Zhang
Journal:  J Biol Chem       Date:  2015-10-19       Impact factor: 5.157

2.  Toll-like receptor 9 deficiency induces osteoclastic bone loss via gut microbiota-associated systemic chronic inflammation.

Authors:  Peng Ding; Qiyuan Tan; Zhanying Wei; Qiyu Chen; Chun Wang; Luyue Qi; Li Wen; Changqing Zhang; Chen Yao
Journal:  Bone Res       Date:  2022-05-27       Impact factor: 13.362

3.  Identification of a Novel Osteogenetic Oligodeoxynucleotide (osteoDN) That Promotes Osteoblast Differentiation in a TLR9-Independent Manner.

Authors:  Yuma Nihashi; Mana Miyoshi; Koji Umezawa; Takeshi Shimosato; Tomohide Takaya
Journal:  Nanomaterials (Basel)       Date:  2022-05-14       Impact factor: 5.719

4.  Role of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease.

Authors:  Mikihito Kajiya; Gabriela Giro; Martin A Taubman; Xiaozhe Han; Marcia P A Mayer; Toshihisa Kawai
Journal:  J Oral Microbiol       Date:  2010-11-08       Impact factor: 5.474

5.  CpG oligodeoxynucleotides inhibit the proliferation and osteoclastic differentiation of RAW264.7 cells.

Authors:  Yi Zheng; Wenwen Yu; Hongyan Li; Hongbing Lin; Zhen Chen; Huishan Chen; Peipei Zhang; Yue Tian; Xiaowei Xu; Yuqin Shen
Journal:  RSC Adv       Date:  2020-04-15       Impact factor: 4.036

6.  CpG Oligodeoxynucleotides Inhibit RANKL-Induced Osteoclast Formation by Upregulating A20 Deubiquitinase in RAW 264.7 Cells.

Authors:  Seong-Kyu Kim; Jung-Yoon Choe; Ki-Yeun Park
Journal:  Mediators Inflamm       Date:  2022-08-31       Impact factor: 4.529

Review 7.  The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis.

Authors:  Danilo Pagliari; Francesco Ciro Tamburrelli; Gianfranco Zirio; Estelle E Newton; Rossella Cianci
Journal:  Anal Cell Pathol (Amst)       Date:  2015-09-30       Impact factor: 2.916

Review 8.  Roles of Mitogen-Activated Protein Kinases in Osteoclast Biology.

Authors:  Kyunghee Lee; Incheol Seo; Mun Hwan Choi; Daewon Jeong
Journal:  Int J Mol Sci       Date:  2018-10-01       Impact factor: 5.923

9.  The involvement of Toll-like receptor 9 in the pathogenesis of erosive autoimmune arthritis.

Authors:  Anita Fischer; Shahla Abdollahi-Roodsaz; Christina Böhm; Birgit Niederreiter; Brigitte Meyer; Anthony C Y Yau; Erik Lönnblom; Leo A B Joosten; Marije Koenders; Christian H K Lehmann; Diana Dudziak; Gerhard Krönke; Rikard Holmdahl; Günter Steiner
Journal:  J Cell Mol Med       Date:  2018-07-11       Impact factor: 5.310

Review 10.  Finding a Toll on the Route: The Fate of Osteoclast Progenitors After Toll-Like Receptor Activation.

Authors:  Pedro P C Souza; Ulf H Lerner
Journal:  Front Immunol       Date:  2019-07-17       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.